{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T18:29:40Z","timestamp":1750184980026},"reference-count":56,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, there is no standard treatment for recurrence or unresectable tumors. Almost 50% of IMTs carry <jats:italic>ALK<\/jats:italic> gene rearrangement that can be treated using <jats:italic>ALK<\/jats:italic> inhibitors, but therapeutic options for <jats:italic>ALK<\/jats:italic>-negative tumors are limited. This report describes a woman aged 22 years with unresectable <jats:italic>ALK<\/jats:italic>-negative IMT. Next-generation sequencing revealed a <jats:italic>TFG-ROS1<\/jats:italic> fusion, and she had a partial response to the <jats:italic>ROS1<\/jats:italic> inhibitor ceritinib. This report provides the first published demonstration of a patient with IMT with <jats:italic>ROS1<\/jats:italic> fusion successfully treated using ceritinib. Our study suggests that targeting <jats:italic>ROS1<\/jats:italic> fusions using the small molecule inhibitor shows promise as an effective therapy in patients with IMT carrying this genetic alteration, but this requires further investigation in large clinical trials.<\/jats:p>","DOI":"10.6004\/jnccn.2019.7360","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T20:06:32Z","timestamp":1575576392000},"page":"1459-1462","source":"Crossref","is-referenced-by-count":18,"title":["Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion"],"prefix":"10.6004","volume":"17","author":[{"given":"Yong","family":"Li","sequence":"first","affiliation":[{"name":"aDepartment of Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Chen","sequence":"additional","affiliation":[{"name":"aDepartment of Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Qu","sequence":"additional","affiliation":[{"name":"aDepartment of Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Ming","family":"Fan","sequence":"additional","affiliation":[{"name":"aDepartment of Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"aDepartment of Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[{"name":"bDepartment of Pathology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaojie","family":"Zheng","sequence":"additional","affiliation":[{"name":"cOrigiMed, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"cOrigiMed, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"aDepartment of Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"ref261","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/annonc\/mdw405","article-title":"Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jcp.2007.049387","article-title":"Inflammatory myofibroblastic tumours: where are we now?","volume":"61","author":"Gleason","year":"2008","journal-title":"J Clin Pathol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jtho.2018.12.003","article-title":"Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements","volume":"14","author":"Chang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"key":"ref01","first-page":"364","article-title":"Inflammatory myofibroblastic tumor: cytogenetic evidence supporting clonal origin","volume":"11","author":"Su","year":"1998","journal-title":"Mod Pathol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/modpathol.3880352","article-title":"ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor","volume":"14","author":"Coffin","year":"2001","journal-title":"Mod Pathol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1177\/0300060518780873","article-title":"Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report","volume":"46","author":"Takahashi","year":"2018","journal-title":"J Int Med Res"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov"},{"key":"ref281","first-page":"364","article-title":"Inflammatory myofibroblastic tumor: cytogenetic evidence supporting clonal origin","volume":"11","author":"Su","year":"1998","journal-title":"Mod Pathol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"Abstract 1538","DOI":"10.1200\/JCO.2017.35.15_suppl.1538","article-title":"A clinical and genomic profile of inflammatory myofibroblastic tumors [abstract]","volume":"35","author":"Daniel","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2018.12.016","article-title":"Case report: crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor","volume":"128","author":"Mai","year":"2019","journal-title":"Lung Cancer"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/modpathol.3880352","article-title":"ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor","volume":"14","author":"Coffin","year":"2001","journal-title":"Mod Pathol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2018.12.016","article-title":"Case report: crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor","volume":"128","author":"Mai","year":"2019","journal-title":"Lung Cancer"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1177\/0300060518780873","article-title":"Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report","volume":"46","author":"Takahashi","year":"2018","journal-title":"J Int Med Res"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cancergen.2017.03.005","article-title":"Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma","volume":"212\u2013213","author":"Rossing","year":"2017","journal-title":"Cancer Genet"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2147\/DDDT.S113500","article-title":"Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy","volume":"11","author":"Santarpia","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PAS.0000000000000404","article-title":"Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement","volume":"39","author":"Antonescu","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.6004\/jnccn.2017.7031","article-title":"Inflammatory myofibroblastic tumor driven by novel NUMA1-ALK fusion responds to ALK inhibition","volume":"16","author":"Rao","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/01.pas.0000213393.57322.c7","article-title":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","volume":"31","author":"Coffin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2147\/DDDT.S113500","article-title":"Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy","volume":"11","author":"Santarpia","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2016.07.002","article-title":"Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity","volume":"99","author":"Ono","year":"2016","journal-title":"Lung Cancer"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"Abstract 1538","DOI":"10.1200\/JCO.2017.35.15_suppl.1538","article-title":"A clinical and genomic profile of inflammatory myofibroblastic tumors [abstract]","volume":"35","author":"Daniel","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00000478-199508000-00001","article-title":"Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases","volume":"19","author":"Coffin","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/PAT.0000000000000050","article-title":"WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition","volume":"46","author":"Jo","year":"2014","journal-title":"Pathology"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/modpathol.2014.165","article-title":"Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors","volume":"28","author":"Hornick","year":"2015","journal-title":"Mod Pathol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jcp.2007.049387","article-title":"Inflammatory myofibroblastic tumours: where are we now?","volume":"61","author":"Gleason","year":"2008","journal-title":"J Clin Pathol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1073\/pnas.242741799","article-title":"Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma","volume":"100","author":"Charest","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","article-title":"An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00000478-199508000-00001","article-title":"Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases","volume":"19","author":"Coffin","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/modpathol.2014.165","article-title":"Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors","volume":"28","author":"Hornick","year":"2015","journal-title":"Mod Pathol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/01.pas.0000213393.57322.c7","article-title":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","volume":"31","author":"Coffin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/annonc\/mdw405","article-title":"Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann Oncol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","article-title":"An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms","volume":"67","author":"Zou","year":"2007","journal-title":"Cancer Res"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1073\/pnas.242741799","article-title":"Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma","volume":"100","author":"Charest","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"115","DOI":"10.6004\/jnccn.2017.7031","article-title":"Inflammatory myofibroblastic tumor driven by novel NUMA1-ALK fusion responds to ALK inhibition","volume":"16","author":"Rao","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol Res"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cancergen.2017.03.005","article-title":"Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma","volume":"212\u2013213","author":"Rossing","year":"2017","journal-title":"Cancer Genet"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/PAT.0000000000000050","article-title":"WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition","volume":"46","author":"Jo","year":"2014","journal-title":"Pathology"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jtho.2018.12.003","article-title":"Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements","volume":"14","author":"Chang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PAS.0000000000000404","article-title":"Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement","volume":"39","author":"Antonescu","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2016.07.002","article-title":"Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity","volume":"99","author":"Ono","year":"2016","journal-title":"Lung Cancer"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/17\/12\/article-p1459.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T19:42:42Z","timestamp":1596829362000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/17\/12\/article-p1459.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":56,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2019.7360","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}